Research ADCs
Related Resources for this page:
- Biological Pathways
- Pipeline Molecules
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- HER Signaling
- How are ADCs designed to work?
- Hypoxic tumor environment promotes angiogenesis
- Glossary
- Monoclonal antibody
- Regulation of VEGF expression
- Research ADCs
- Serum VEGF as a clinical marker
- Slide decks and videos
- Stable linker
- Summary
- Summary
- Summary
- Trastuzumab Emtansine (T-DM1)
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- What are ADCs?
- Antibody-Drug conjugates
- Glycoengineered Antibodies
- HER Signaling
- Hypoxic tumor environment promotes angiogenesis
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Non-Antibody Biologics
- Apoptosis
- Hypoxic tumor environment promotes angiogenesis
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Targeted Small Molecules
- Apoptosis
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Multiple Myeloma
- PI3K Inhibitor (GDC-0941)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Vismodegib (GDC-0449) Smoothened Inhibitor
- Traditional Monoclonal Antibodies
- Glossary
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Antibody-Drug Conjugates
Share
Targeting cancers with ADCs
Decades of research have made a new generation of ADCs possible1-4
The potential of ADCs has been enhanced by several factors, including2,3,5
- A more clinically relevant choice of target antigens
- More potent cytotoxics in conjugation with linkers of improved stability
- A greatly expanded knowledge of ADC technology, cancer biology,
and pharmacology
Potential methods for targeting different cancers with ADCs involve
- Creating new monoclonal antibodies specific for the preferentially expressed antigen and linking them to appropriate cytotoxics6,7
- Using existing monoclonal antibodies to deliver a potent cytotoxic2,6
Combining ADCs with conventional chemotherapeutic agents may be advantageous under certain clinical conditions. Preclinical studies suggest this may be due to multiple mechanisms of action, including2,8
- The anticancer effect of the ADC on the target cells
- The effect of the chemotherapy on the stromal cells
- A combination of these mechanisms
References:
- 1.
- Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008;14:6171-6180.
- 2.
- Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154-169.
- 3.
- Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721-2729.
- 4.
- Ghose T, Blair AH. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J Natl Cancer Inst. 1978;61:657-676.
- 5.
- Alley SC, Zhang X, Okeley NM, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009;330:932-938.
- 6.
- Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
- 7.
- Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255:232-240.
- 8.
- Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber H-P. Combination of the anti-CD30-auristatin- E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142:69-73.